Wechat official account

 

Headquarters: Building F2, 88 Kechuang, 6th St., Beijing , China
Beijing Office : Suite 2105, Building T2, Dazu Square, Beijing , China
Shanghai Office: 595 North Caoxi Road  Building A Suite 6009 , Shanghai China
Boston Office: 99 Hayden Ave, Lexington, MA 02421, US

Tel: +86  010-56315466

Fax: +86  010-56315314

 

 

Copyright: JACOBIO PHARMACEUTICALS GROUP CO., LTD.   Beijing ICP B 17065868-1   

 

 

Page view:
Clinical Stage Candidates
Clinical Stage Condidates
Assets
Programs
Indications
IND
Phase I
Phase IIa
Recent progress
Upcoming milestone(expected)

JAB-3068 SHP2

 Mono
Solid tumors
US trial
 
 
Mono
ESCC,  HNSCC,  NSCLC
China trial
 
 
Combo w/PD-1 mAb
ESCC,  HNSCC,  NSCLC
China trial
IND approved and
FPI in April 2021
 

JAB-3312 SHP2

Mono
Solid tumors
US trial
 
 
 Mono
Solid tumors
China trial
 
 
Mono
BRAF class 3/NF1 LOF
mutant solid tumors
US trial
 
Ph IIa FPI
(2021 Q4)
Combo w/PD-1 mAb
ESCC,  HNSCC,  NSCLC
Global trial
IND approved and
FPI in May 2021
 
Combo w/MEKi
KRAS mut  CRC, Pancreatic cancer
Global trial
IND approved and
FPI in May 2021
 
Combo w/KRAS G12Ci
KRAS G12C mut+
NSCLC,  CRC
Global trial
 
Global Ph Ib/IIa FPI (2021 Q4)
JAB-8263
BET
(MYC)
Mono
Solid tumors
US trial
 
 
Mono
Solid tumors
China trial
IND approved and trials
initiated in 2021 Q1
 
Mono
MF  and  AML
China trial
IND approved and
FPI in April 2021
 
JAB-21822
KRAS G12C
(SHP2/RAS)
Mono
NSCLC,  CRC
US trial
IND approved in May 2021
FPI (2021 Q3)
Mono
NSCLC,  CRC
China trial
IND approved in May
FPI in July 2021
 
Mono
NSCLC
Global trial
IND submitted in August 2021
FPI
(2022 1H)
Mono
NSCLC with specific co-mutation
Global trial
IND submitted in August 2021
FPI
(2022 1H)
Combo w/PD-1 mAb
NSCLC
China trial
IND submitted in August 2021
FPI
(2022 1H)
Combo w/SHP2i
NSCLC,  CRC
China trial
 
FPI (2022 1H)
Combo w/EGFR mAb
CRC
China trial
 
 
IND-enabling Stage Candidates
IND-Enabling
Assets
Programs
Indications
Lead optimization
Candidate
IND-enabling
Recent
development
Upcoming milestone(expected)
JAB-BX102
CD73 mAb
(IO)
PD-(L)1 resistant CRC
melanoma and CRPC
 
GLP-tox and GMP production
of DS/DP completed
IND
(2021 Q3)
JAB-6343
FGFR4
(RTK)
HCC
 
GLP-tox and GMP
API manufacturing completed
IND
(2021 2H)
JAB-2485
Aurora A
(MYC/RB)
RB1-deficient tumors
 
GLP-tox and GMP production
of DS/DP ongoing
IND
(2021 2H)
JAB-24000
Undisclosed
(Tumor metabolic pathway)
NSCLC,  HNSCC
 
Candidate nominated,  entering into
IND-enabling studies in Mar 2021
IND
(2022)
JAB-BX300
Undisclosed
(Tumor metabolic pathway)
PDAC,  CRC
 
Candidate nominated,  entering into
IND-enabling studies in Mar 2021
IND
(2022)
Lead
Optimization
JAB-26000
Undisclosed
(I/0)
SCLC,  HNSCC,  ESCC
 
Lead series identified and patent filed
in Jan 2021
IND
(2022-2023)
JAB-22000
KRAS G12D
(RAS)
PDAC, CRCNSCLC
 
Lead series identified and patent filed
in Jan 2021
IND
(2022-2023)
Last update date: Aug. 31 2021